No Data
No Data
FDA Approves ScPharmaceuticals' Furoscix SNDA for Oedema in CKD
Analysts Offer Insights on Healthcare Companies: ScPharmaceuticals (SCPH), Intuitive Surgical (ISRG) and Labcorp Holdings (LH)
Strategic Market Expansion and Strong Sales Foundation Drive Buy Rating for ScPharmaceuticals
Express News | ScPharmaceuticals Inc: Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025
Express News | ScPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease
H.C. Wainwright Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $18
Unlock the Full List
Trailside22 : well done dr.
CloverJen : thank you
Common and basic : thanks!
MarshmallowQ : Friends, what will you buy tomorrow?
MarshmallowQ : Anyone in $Aclarion (ACON.US)$ ?
View more comments...